Q-omics provides the consensus-scored RAB4A profile across patient tissues and cancer cell-line models. RAB4A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RAB4A is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, RAB4A protein abundance shows 23,594 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, LIHC, and GBM as cancer lineages where RAB4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB4A survival associations across molecular data types. RAB4A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB4A RNA expression–survival associations across cancer types. High RAB4A expression shows unfavorable associations in ACC, SCLC, ESCA and KIRP, but favorable associations in KIRC and COAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RAB4A RNA expression.
This table summarizes RAB4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for RAB4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB4A shows lower tumor expression in KICH and THCA and higher tumor expression in LIHC, KIRC, KIRP and LUSC. The LIHC box plot shows higher RAB4A RNA expression in tumor versus normal tissue (log2 FC = +1.155, t-test p < 0.001).
This table shows molecular features associated with RAB4A in patient tissues and cancer cell lines. In patient samples, RAB4A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
